SCO-267 is under development for the treatment of non-alcoholic steatohepatitis (NASH), diabetes, nonalcoholic fatty liver disease and obesity. It acts by targeting GPR40. It is administered through ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Increasing average concentrations of sotatercept improved 6-minute walk distance, pulmonary vascular resistance, and levels of NT-proBNP.

Cosmos Health (COSM) announced the appointment of Professor Dimitrios Trafalis as Head of Oncology at the company’s Research and Development ...

China and the World Anti-Doping Agency say that positive tests for a banned drug among elite Chinese swimmers were a result ...

Anavex Life Sciences Corp. shares rocketed over 27% on Monday, hitting their highest levels since February 2023, fueled by a ...

To design safe and effective drugs, the pharmacology of how drugs work in relationship to the body must be understood. This ...

New research provides insight into how bioactive compounds from Mediterranean plants like garlic and olive can potentially ...

In the published article, there was an error in the Funding statement. The funding details for “Jinan Science and Technology Development Plan - Clinical Medicine ...

Phase I clinical trial of a drug was successfully completed, with promise to treat Alzheimer's and other neurodegenerative diseases. The compound, named VU319, is the first end-to-end drug discovery ...

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug ...

The identification of genes involved in diseases is one of the major challenges of biomedical research. Researchers at the ...